Undisclosed ADC
/ Samsung
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
December 02, 2025
Samsung Bioepis has submitted an investigational new drug (IND) application for a phase 1 clinical trial of an antibody-drug conjugate (ADC) drug candidate to the U.S. Food and Drug Administration (FDA)
(Chosun Biz)
- "The company is aiming to enter a global phase 1 trial next year and to produce interim results."
IND • New P1 trial • Bladder Cancer
1 to 1
Of
1
Go to page
1